

FOR IMMEDIATE RELEASE

Sun Pharma Commits Donation of Medicines and Hand Sanitizers to Support India's COVID-19 Pandemic Response

- *Will donate Hydroxychloroquine, Azithromycin and other related drugs*
- *Has re-purposed its liquid manufacturing facility in India to produce high-quality hand sanitizers*
- *Salutes the entire medical fraternity and staff for their selfless service in these testing times*

Mumbai, India, March 27, 2020 – Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced its commitment to donate INR 250 Million (Indian Rupees Two Hundred and Fifty Million) of Hydroxychloroquine (HCQS), Azithromycin, other related drugs and hand sanitizers to support India's COVID-19 pandemic response.

Sun Pharma salutes the entire medical & support fraternity including doctors, nurses and healthcare workers who are selflessly providing care to all affected patients in India. To help these front-line warriors, the company has re-purposed its liquid manufacturing facility in India to produce high-quality hand sanitizers and will make them available to healthcare professionals serving their communities and the nation.

Sun Pharma is committed to fight the COVID-19 pandemic and has instituted work from home for all team members who are able to work remotely at all its locations. The company is proud of its passionate and dedicated team members in Manufacturing, IT, Quality, Finance, HR and Supply Chain, who are ensuring continued supply of medicines to address the needs of patients.

Sun Pharma urges people both in India and around the world not to hoard medicines, in order to make sure they are available to those in genuine need. The company is committed to working closely with the governments and relevant stakeholders to ensure there is uninterrupted supply of medicines. Sun Pharma is constituting a task force to handle the distribution of these products in India.

The National Task Force¹ for COVID-19 has recommended the prophylactic use of HCQS for high risk population². The approved indications of HCQS are malaria, lupus erythematosus and rheumatoid arthritis. The approved indications of Azithromycin are Uncomplicated Skin/Skin Structure Infections, Community-Acquired Pneumonia, etc. HCQS is currently being studied by the World Health Organization (WHO) for use in-conjunction with Azithromycin to treat COVID-19.

References:

1. <https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf>
2. High Risk Individuals have been classified as
 - a. Asymptomatic Healthcare workers involved in the care of suspected or confirmed cases of COVID-19
 - b. Asymptomatic household contacts of laboratory confirmed cases

Disclaimer:

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied.

About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 7% of annual revenues in R&D. For further information, please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live.

Contacts:

Investors:

Nimish Desai
Tel +91 22 4324 4324, Xtn 2778
Tel Direct +91 22 4324 2778
Mobile +91-98203 30182
E mail nimish.desai@sunpharma.com

Media:

Gaurav Chugh
Tel +91 22 4324 4324, Xtn 5373
Tel Direct +91 22 4324 5373
Mobile +91 98104 71414
E mail gaurav.chugh@sunpharma.com